Top 5 CRISPR Stocks To Buy

2. Agilent Technologies, Inc. (NYSE:A)

Number of Hedge Fund Holders: 48

Agilent Technologies, Inc. (NYSE:A) offers solutions for life sciences, applied chemical, and diagnostics markets. The company’s Diagnostics and Genomics division provides various arrays and software for DNA analysis and interpretation, including mutation detection, genotyping, gene copy number determination, gene rearrangement identification, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment, genetic data management, and oligonucleotide synthesis. Agilent Technologies, Inc. (NYSE:A) is one of the best CRISPR stocks to invest in. 

On March 1, Credit Suisse analyst Dan Leonard increased Agilent Technologies, Inc. (NYSE:A)’s price target from $165 to $170 and maintained an Outperform rating on the stock after a strong fourth quarter. The analyst believes that the company’s potential to grow towards the upper end of the industry across various macro environments is not fully appreciated by the market.

According to Insider Monkey’s fourth quarter database, 48 hedge funds were bullish on Agilent Technologies, Inc. (NYSE:A), compared to 46 funds in the last quarter. Ian Simm’s Impax Asset Management is the largest stakeholder of the company, with 3.92 million shares worth $586.7 million. 

Cooper Investors made the following comment about Agilent Technologies, Inc. (NYSE:A) in its Q4 2022 investor letter:

“Agilent Technologies, Inc. (NYSE:A) finished a great year with +12% organic growth after a +15% year in 2021. As a supplier of liquid chromatography/ mass spectrometry instruments into the life sciences industry, Agilent enjoyed a period of supernormal growth over the 2020-2021 COVID pandemic. Like several of our healthcare and diagnostics investments Agilent de-rated quite sharply in the first half of 2022 as the market ‘faded’ the decline in COVID testing revenues. In our view this short term volatility obscures the high quality of Agilent’s business and long term growth opportunities. One example is environmental testing as mandated by the US EPA where US$4bn of funding in the infrastructure bill has been put aside for PFAS testing. As CEO Mike McMullen noted on the last call, ‘it’s the first time in my career we’ve seen this kind of government money coming in’.”